Conference Coverage
Conference Coverage
Gene profiling predicted responses to colorectal, pancreatic cancer treatment
Major finding: Gene expression patterns identified three subtypes of stage II or III colorectal cancer with different responses to 5-FU–based...
Conference Coverage
Add-on nab-paclitaxel extends survival in metastatic pancreatic cancer
Major Finding: Median overall survival in patients with metastatic pancreatic cancer increased from 6.7 months on gemcitabine to 8.5 months on nab...
Conference Coverage
Fewer acute GvHD cases after stem-cell transplant with vorinostat
Major Finding: The cumulative incidence of grade 2-4 acute graft-versus-host disease at day 100 after hematopoietic stem-cell transplant was 22%...
Conference Coverage
Second-line agent for gastroesophageal adenocarcinoma ups survival
Major Finding: Patients who failed first-line treatment for metastatic gastric or gastroesophageal junction adenocarcinoma lived a median of 5.2...
Conference Coverage
New tool predicts late recurrence in breast cancer
Major Finding: Among patients who remained disease free at 5 years, the 61% with a low baseline BCI score had a 3.5% rate of distant recurrence...
Conference Coverage
Lenalidomide branches out to lymphoma therapy
Major Finding: In a phase II study, lenalidomide added to CHOP chemotherapy and rituximab produced a 92% overall response rate in elderly patients...
Conference Coverage
Risk of anal cancer is high in HIV-infected people
Conference Coverage
New geriatric assessments aid cancer treatment decisions
Conference Coverage
SLN surgery may suffice for node-positive breast cancer
Major Finding: SLN surgery correctly identified axillary nodal status in 91.2% of patients.
Conference Coverage
Diabetes confers 27% increase in breast cancer risk
Major Finding: Diabetes is associated with a 27% increased risk of breast cancer, with the elevated risk restricted to postmenopausal women with...
Conference Coverage
'Highest response rate ever reported' in relapsed mantle cell lymphoma
Major Finding: In an efficacy cohort of 110 patients with relapsed or refractory mantle cell lymphoma, 22% had a complete response and 46% a...